FDA's Drug Center Permits Some Combo Product Software To Be Submitted As DMFs
Executive Summary
New draft guidance from the US agency allows electronics or software that will be used across multiple combination products to be submitted as a Type V drug master file (DMF), potentially streamlining the assessment process.
You may also be interested in...
Combination Products: US FDA Aims For Limited Two-Application Solutions
In announcing guidance stating one application generally is sufficient for a combination product, FDA asks for comments on situations where two would be needed.
Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
But sponsors should sometimes seek advisory comment. Agency explains that most drug-use-related apps will be considered promotional labeling. FDA seeking feedback from a variety of stakeholders on its discussion proposal for regulating prescription-focused software.
US FDA Preparing For New 'Combination Product Agreement Meetings'
Cures legislation offers more development certainty for sponsors by allowing informal agreements with the agency on pre- and postmarket issues.